Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company…